vs
Side-by-side financial comparison of PAMT CORP (PAMT) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.
PAMT CORP is the larger business by last-quarter revenue ($141.3M vs $103.7M, roughly 1.4× Twist Bioscience Corp). PAMT CORP runs the higher net margin — -20.7% vs -29.4%, a 8.7% gap on every dollar of revenue. On growth, Twist Bioscience Corp posted the faster year-over-year revenue change (16.9% vs -15.1%). PAMT CORP produced more free cash flow last quarter ($-25.0M vs $-34.8M).
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
PAMT vs TWST — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $141.3M | $103.7M |
| Net Profit | $-29.3M | $-30.5M |
| Gross Margin | — | 52.0% |
| Operating Margin | -27.0% | -31.7% |
| Net Margin | -20.7% | -29.4% |
| Revenue YoY | -15.1% | 16.9% |
| Net Profit YoY | 7.4% | 3.4% |
| EPS (diluted) | $-1.38 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $141.3M | $103.7M | ||
| Q3 25 | $150.3M | — | ||
| Q2 25 | $151.1M | — | ||
| Q1 25 | $155.3M | — | ||
| Q4 24 | $166.5M | — | ||
| Q3 24 | $182.6M | — | ||
| Q2 24 | $182.9M | — | ||
| Q1 24 | $182.6M | — |
| Q4 25 | $-29.3M | $-30.5M | ||
| Q3 25 | $-5.6M | — | ||
| Q2 25 | $-9.6M | — | ||
| Q1 25 | $-8.1M | — | ||
| Q4 24 | $-31.6M | — | ||
| Q3 24 | $2.4M | — | ||
| Q2 24 | $-2.9M | — | ||
| Q1 24 | $281.0K | — |
| Q4 25 | — | 52.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -27.0% | -31.7% | ||
| Q3 25 | -3.8% | — | ||
| Q2 25 | -7.3% | — | ||
| Q1 25 | -5.9% | — | ||
| Q4 24 | -22.6% | — | ||
| Q3 24 | 1.3% | — | ||
| Q2 24 | -0.4% | — | ||
| Q1 24 | -0.4% | — |
| Q4 25 | -20.7% | -29.4% | ||
| Q3 25 | -3.7% | — | ||
| Q2 25 | -6.4% | — | ||
| Q1 25 | -5.2% | — | ||
| Q4 24 | -19.0% | — | ||
| Q3 24 | 1.3% | — | ||
| Q2 24 | -1.6% | — | ||
| Q1 24 | 0.2% | — |
| Q4 25 | $-1.38 | $-0.50 | ||
| Q3 25 | $-0.27 | — | ||
| Q2 25 | $-0.46 | — | ||
| Q1 25 | $-0.37 | — | ||
| Q4 24 | $-1.44 | — | ||
| Q3 24 | $0.11 | — | ||
| Q2 24 | $-0.13 | — | ||
| Q1 24 | $0.01 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $83.7M | $197.9M |
| Total DebtLower is stronger | $333.9M | — |
| Stockholders' EquityBook value | $210.5M | $456.1M |
| Total Assets | $697.9M | $638.1M |
| Debt / EquityLower = less leverage | 1.59× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $83.7M | $197.9M | ||
| Q3 25 | $115.6M | — | ||
| Q2 25 | $117.3M | — | ||
| Q1 25 | $102.7M | — | ||
| Q4 24 | $110.7M | — | ||
| Q3 24 | $92.3M | — | ||
| Q2 24 | $114.0M | — | ||
| Q1 24 | $125.8M | — |
| Q4 25 | $333.9M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $325.6M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $210.5M | $456.1M | ||
| Q3 25 | $239.5M | — | ||
| Q2 25 | $244.9M | — | ||
| Q1 25 | $269.6M | — | ||
| Q4 24 | $277.5M | — | ||
| Q3 24 | $308.9M | — | ||
| Q2 24 | $306.7M | — | ||
| Q1 24 | $314.6M | — |
| Q4 25 | $697.9M | $638.1M | ||
| Q3 25 | $715.2M | — | ||
| Q2 25 | $707.9M | — | ||
| Q1 25 | $712.6M | — | ||
| Q4 24 | $741.7M | — | ||
| Q3 24 | $756.7M | — | ||
| Q2 24 | $733.5M | — | ||
| Q1 24 | $746.4M | — |
| Q4 25 | 1.59× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.17× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-5.8M | $-24.8M |
| Free Cash FlowOCF − Capex | $-25.0M | $-34.8M |
| FCF MarginFCF / Revenue | -17.7% | -33.5% |
| Capex IntensityCapex / Revenue | 13.6% | 9.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-23.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-5.8M | $-24.8M | ||
| Q3 25 | $5.9M | — | ||
| Q2 25 | $12.2M | — | ||
| Q1 25 | $5.0M | — | ||
| Q4 24 | $15.2M | — | ||
| Q3 24 | $15.5M | — | ||
| Q2 24 | $18.7M | — | ||
| Q1 24 | $9.6M | — |
| Q4 25 | $-25.0M | $-34.8M | ||
| Q3 25 | $2.5M | — | ||
| Q2 25 | $5.9M | — | ||
| Q1 25 | $-6.8M | — | ||
| Q4 24 | $-39.9M | — | ||
| Q3 24 | $-33.6M | — | ||
| Q2 24 | $4.1M | — | ||
| Q1 24 | $-12.2M | — |
| Q4 25 | -17.7% | -33.5% | ||
| Q3 25 | 1.7% | — | ||
| Q2 25 | 3.9% | — | ||
| Q1 25 | -4.4% | — | ||
| Q4 24 | -24.0% | — | ||
| Q3 24 | -18.4% | — | ||
| Q2 24 | 2.2% | — | ||
| Q1 24 | -6.7% | — |
| Q4 25 | 13.6% | 9.6% | ||
| Q3 25 | 2.3% | — | ||
| Q2 25 | 4.2% | — | ||
| Q1 25 | 7.6% | — | ||
| Q4 24 | 33.1% | — | ||
| Q3 24 | 26.9% | — | ||
| Q2 24 | 8.0% | — | ||
| Q1 24 | 12.0% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 6.44× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 34.11× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PAMT
| Freight Transportation Service | $123.1M | 87% |
| Fuel Surcharge | $18.2M | 13% |
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
